Several other research firms have also commented on CTLT. Zacks Investment Research raised Catalent from a sell rating to a hold rating in a research report on Monday, October 1st. UBS Group started coverage on Catalent in a research note on Tuesday, October 9th. They set a neutral rating and a $48.00 target price for the company. JPMorgan Chase & Co. raised their target price on Catalent from $50.00 to $55.00 and gave the company an overweight rating in a research note on Wednesday, August 29th. First Analysis upgraded Catalent from a neutral rating to an outperform rating and lowered their target price for the company from $47.00 to $43.00 in a research note on Wednesday. Finally, ValuEngine downgraded Catalent from a buy rating to a hold rating in a research note on Tuesday. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $48.11.
NYSE:CTLT traded down $0.14 during mid-day trading on Wednesday, hitting $37.51. The company had a trading volume of 1,133,400 shares, compared to its average volume of 857,435. The company has a debt-to-equity ratio of 1.44, a current ratio of 2.05 and a quick ratio of 1.79. Catalent has a 1 year low of $34.24 and a 1 year high of $47.87. The firm has a market capitalization of $5.48 billion, a PE ratio of 23.59, a price-to-earnings-growth ratio of 2.24 and a beta of 1.45.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, November 6th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.24 by $0.04. Catalent had a return on equity of 19.13% and a net margin of 2.65%. The company had revenue of $551.80 million for the quarter, compared to analyst estimates of $582.44 million. During the same period last year, the company posted $0.21 earnings per share. The firm’s revenue was up 1.5% compared to the same quarter last year. Equities analysts anticipate that Catalent will post 1.72 EPS for the current year.
In related news, SVP Lance Miyamoto sold 6,525 shares of Catalent stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $42.50, for a total value of $277,312.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Donald E. Morel, Jr. purchased 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 13th. The stock was purchased at an average price of $43.00 per share, with a total value of $430,000.00. The disclosure for this purchase can be found here. Insiders have sold 184,335 shares of company stock valued at $8,161,727 over the last 90 days. Insiders own 1.40% of the company’s stock.
A number of large investors have recently bought and sold shares of CTLT. JPMorgan Chase & Co. grew its stake in Catalent by 29.5% in the third quarter. JPMorgan Chase & Co. now owns 7,976,203 shares of the company’s stock worth $363,316,000 after purchasing an additional 1,819,020 shares in the last quarter. Millennium Management LLC grew its stake in Catalent by 4,244.2% in the second quarter. Millennium Management LLC now owns 1,200,267 shares of the company’s stock worth $50,279,000 after purchasing an additional 1,172,638 shares in the last quarter. Janus Henderson Group PLC grew its stake in Catalent by 13.0% in the third quarter. Janus Henderson Group PLC now owns 7,234,661 shares of the company’s stock worth $329,539,000 after purchasing an additional 833,924 shares in the last quarter. BlackRock Inc. grew its stake in Catalent by 7.0% in the third quarter. BlackRock Inc. now owns 12,628,951 shares of the company’s stock worth $575,248,000 after purchasing an additional 822,258 shares in the last quarter. Finally, Redmile Group LLC acquired a new position in Catalent in the second quarter worth about $27,725,000. Institutional investors and hedge funds own 92.08% of the company’s stock.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
See Also: Intrinsic Value
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.